## Chlamydial Conjunctivitis (Trachoma) — Treatment ### Clinical Context The patient presents with chronic follicular conjunctivitis, keratitis, conjunctival scarring, and trichiasis caused by *Chlamydia trachomatis* serovars A–C — the classic presentation of **trachoma** (endemic keratoconjunctivitis), the leading infectious cause of preventable blindness worldwide. **Key Point:** Chlamydial conjunctivitis requires systemic antibiotic therapy because the organism is an obligate intracellular pathogen; topical agents alone cannot achieve adequate intracellular concentrations. ### Drug of Choice **Azithromycin 1 g orally once weekly for 3 weeks** (or a single 1 g dose in mild/community settings) is the current **drug of choice** for trachoma per WHO guidelines, AAO recommendations, and standard ophthalmology references (Khurana, Parson's). | Drug | Dose | Duration | Notes | |------|------|----------|-------| | **Azithromycin** | 1 g weekly | 3 weeks | **DOC** — superior compliance, safe in children & pregnancy, WHO-endorsed MDA agent | | Doxycycline | 100 mg BD | 3 weeks | Acceptable alternative; contraindicated in pregnancy & children <8 yrs | | Erythromycin ointment | Topical QID | 6 weeks | Adjunct only; inadequate as monotherapy for active trachoma | | Ofloxacin drops | Topical hourly | 2 weeks | Topical only; insufficient for systemic/intracellular disease | ### Why Azithromycin is Preferred Over Doxycycline 1. **Single-dose / weekly regimen:** Dramatically improves compliance compared to doxycycline's twice-daily 3-week course. 2. **Intracellular penetration:** Azithromycin achieves very high and sustained intracellular concentrations in epithelial cells and macrophages — ideal for an obligate intracellular pathogen. 3. **Safety profile:** Safe in pregnancy (doxycycline is Category D — teratogenic) and in children, making it suitable for mass drug administration (MDA). 4. **WHO SAFE strategy:** Azithromycin is the cornerstone antibiotic in the WHO-endorsed SAFE strategy (Surgery, Antibiotics, Facial cleanliness, Environmental improvement) for trachoma elimination. 5. **Efficacy:** Clinical trials (including the PRET and TANA studies) confirm non-inferiority or superiority over doxycycline for trachoma eradication. **High-Yield:** Doxycycline 100 mg BD × 3 weeks is an **acceptable alternative** when azithromycin is unavailable or not tolerated, but it is NOT the first-line drug of choice for trachoma in current guidelines. **Clinical Pearl:** In endemic regions, a **single oral dose of azithromycin 1 g** (adults) or **20 mg/kg** (children) is used for mass drug administration — this single-dose strategy has been shown to be as effective as the 3-week topical erythromycin regimen for active trachoma. ### Adjunctive Management - **Topical antibiotics:** Tetracycline or erythromycin eye ointment as adjunct to systemic therapy. - **Surgical correction:** Trichiasis and entropion require surgical intervention (lid rotation procedures) after antimicrobial therapy. - **Public health:** Contact tracing, treatment of household contacts, and community-level MDA in endemic areas. [cite: Khurana AK, Comprehensive Ophthalmology 8e; WHO Guidelines for Trachoma Elimination 2020; Harrison's Principles of Internal Medicine 21e Ch 176; Parson's Diseases of the Eye 23e]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.